| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Bayer AG ADR | Factor XIa (FXIa) and Asundexian - (OCEANIC-STROKE) | Acute non-cardioembolic stroke or high risk transient ischemic attack (TIA) | Phase 3 | Data Released | Oral | Neurology |
| Beam Therapeutics Inc. | Ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) - (BEACON) | Sickle cell disease | BLA Filing | Data Released | Intravenous infusion | Hematology |
| BeiGene Ltd. | Tislelizumab | Squamous non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology | |
| BeiGene Ltd. | BRUKINSA (zanubrutinib) - (Max Foundation trial) | Chronic lymphocytic leukemia (CLL) | Phase 2 | Enrollment Initiation | Oral | Oncology |
| BeiGene Ltd. | DKN-01 plus pembrolizumab | Endometrial cancer | Phase 2 | Trial Planned | intravenous | Oncology |
| BeiGene Ltd. | Ociperlimab (OCI) + Tislelizumab (TIS) - (AdvanTIG-203) | Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Intravenous | Oncology | |
| BeiGene Ltd. | Tislelizumab | Squamous non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology | |
| BeiGene Ltd. | Tislelizumab - (RATIONALE 309) | Nasopharyngeal cancer (RM-NPC) | Phase 3 | Intravenous | Oncology |